Nanoparticle Dissolution Testing Solution from Agilent Technologies
The system gives R&D formulation chemists the ability to manufacture new formulations sooner, while allowing manufacturing teams to supply reliable batches of new drug products for commercial sale in an automated and compliant manner.
The NanoDis System for nanoparticle dissolution testing from Agilent Technologies combines Agilent’s instrumentation and software to provide a system that is automatable and auditable.
The system gives R&D formulation chemists the ability to manufacture new formulations sooner, while allowing manufacturing teams to supply reliable batches of new drug products for commercial sale in an automated and compliant manner.
"Agilent's introduction of the NanoDis System is significant in that it is the first nanoparticle testing solution that allows methods to be easily transferred from R&D to QC, supporting scientists in meeting the requirements of United States Pharmacopeia," said Michael Frank, associate vice-president of global marketing for Agilent’s Liquid Phase Separation division, in a Nov. 23, 2020 company press release. "The NanoDis System can be universally implemented, therefore ensuring that our customers' global laboratory locations deliver the same results every time. Additionally, the NanoDis System is an end-to-end, single-vendor solution that is fully supported by a dedicated global team."
Source: Agilent
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
